Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX) from its SEC filings: 2025 revenue $59,000 (-87% vs the year before), net margin -132642%, free cash flow -$51.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $59,000 |
| Revenue growth | -87% |
| Net income | -$78.3 million |
| Net margin | -132642.4% |
| Free cash flow | -$51.5 million |
| Diluted EPS | $-5.84 |
| Latest quarter (Q3 2025 (calendar)) revenue vs a year earlier | -100% |
| Cash | $85.4 million |
| Long-term debt | $14.3 million |
| Share count, 1 year | +308% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.